Floatz logo

cd4+cd25+ regulatory t cells

Myeloproliferative Disorders

Stanford UniversityCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

6 Active assets in the Myeloproliferative Disorders cohort.

Asset / SponsorPhaseRating
Treg Cells
Stanford University
Phase 2B
Inno-206
OHSU Knight Cancer Institute
Phase 2B
Donor Lymphocyte Preparation Depleted Of Host Functional Alloreactive T-Cells
Kiadis Pharma
Phase 2/3CCC
LEUPROLIDE
Masonic Cancer Center, University of Minnesota
Phase 2CCC
Mesna
Center for International Blood and Marrow Transplant Research
Phase 2CCC

View all 22 →

Same molecule, other indications

cd4+cd25+ regulatory t cells is also rated in:

Advanced Hematologic MalignanciesDormant
CC
Indicative ·
43 / 100
View asset →
Allogeneic Hematopoietic Cell Transplantation (HCT)Dormant
CC
Indicative ·
43 / 100
View asset →
plasma cell myelomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →